IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ap	pplicar	nt(s): Jacob Waugh et al.				
Serial No.:		o.: 10/591,485	Group Art Unit:	1656		
Filed:		November 7, 2007	Examiner:	Samuel W. Liu		
For:		Multi-Component Biological Tr	Confirmation No: 1919 Multi-Component Biological Transport Systems			
P.0	O. Box	sioner for Patents 3. 1450 ria, VA 22313-1450				
		INFORMATION DISC	LOSURE STATEME	ENT		
Sin	••					
		This Information Disclosure State	ement is filed in accord	lance with 37 C.F.R.		
§§	1.56, 1	.97 and 1.98. The items listed on Form	n PTO-1449, a copy of	which is enclosed, are		
ma	de of	record to assist the Patent and Tradema	rk Office in its examin	ation of this application.		
Th	e Exai	miner is respectfully requested to fully of	consider the items and	to independently ascertai		
the	ir teac	hing.				
1.		For each of the following items listed not in the English language, an English thereof or a concise explanation of the	h language translation	of that item or a portion		
2.		For each of the following items listed on the enclosed copy of Form PTO-1449 that not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.				
3.		Any copy of the items listed on the en enclosed with this Information Disclosubmitted to the Patent and Trademark	sure Statement was pre	viously cited by or		
		·				
4.	\boxtimes	No fee is due under 37 C.F.R. §1.17(p since it is being filed in compliance w		Disclosure Statement		
		37 C.F.R. §1.97(b)(1), within tapplication other than a CPA;		ng date of a national		
		37 C.F.R. §1.97(b)(2), within t national stage as set forth in §1		<u> </u>		

		\boxtimes	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
			37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.	
6.	it is being filed in compliance with 37 C.F.R. §1.97(c), after		is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in raph 4 above but before the mailing date of a final action or a notice of ance (where there has been no prior final action):
			A check in the amount of \$180.00 is enclosed in payment of the fee.
			Charge the fee to Deposit Account No. <u>50-3732</u> , Order No
it is being filed in compliance with 37 C.		it is be	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final or a notice of allowance, whichever comes first, but before payment of the issue id is accompanied by:
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and
			e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.
8.		This I	nformation Disclosure Statement is being filed in compliance with:
		a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
		b	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).
		c. 🗌	The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.
9.			by certify that each item of information contained in this Information Disclosure then was first cited in a communication from a foreign patent office in a

963589 v1

US 10/591,485 Docket No. 13720-105074US1

		counterpart foreign application not more than three months prior to the fi Information Disclosure Statement.			
	I hereby certify that no item of information in the Information Disclosure S filed herewith was cited in a communication from a foreign patent office in counterpart foreign application or, to my knowledge after making reasonable was known to any individual designated in §1.56(c) more than three months the filing of this Information Disclosure Statement.				
10.		This document is accompanied by a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application.			
11.		A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).			
		Charge any fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 50-3732, Order No			
	\boxtimes	The Commissioner is hereby authorized to charge any additional fees which may required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13720-105074.			
			Respectfully submitted, KING & SPALDING LLP		
Dated: October 7, 2008 By:			Soseph D. Eng Vs.		
			Jóseph D. Eng, Jr. Reg. No. 54,084		
Correspondence Address:					
King & Spalding LLP					
112	185 Avenue of the Americas				

New York, NY 10036 212-556-2100 Telephone 212-556-2222 Facsimile

963589 v1 -3-